Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26934740 | 1.00 | MEN1 (0.33) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL26934739 | 1.00 | MEN1 (0.33) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL24586835 | 1.00 | MEN1 (0.33) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL24586836 | 1.00 | MEN1 (0.33) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL26937054 | 1.00 | MEN1 (0.33) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL24586112 | 1.00 | MEN1 (0.33) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL24226195 | 0.78 | MEN1 (0.32) | MEN1CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL14721640 | 0.71 | — | — | |
| SCHEMBL26937043 | 0.71 | — | — | |
| SCHEMBL872722 | 0.67 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840495-B2 | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds | THE BROAD INSTITUTE, INC. (US) | 2023-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840495-B2 | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds | PHOSPHO1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GRIN2C | MEN1 472/4885CYP1A2 185/4885CYP3A4 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.